InsidersTradesSigma
Track the CSL LIMITED stock price and the full insider trade history of the company, a listed equity based in Australia. Shares trade on the AU market, under the supervision of ASX. Operating in the Health Care sector, CSL LIMITED has logged 4 insider filings. Market capitalisation: €66.3bn. The latest transaction was reported on 4 June 2026 (Purchase). Among the most active insiders: Gordon Naylor. Every trade is free.
Analysts rate CSL LIMITED Buy (bullish), based on 16 analysts. Average price target: A$137.19.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
CSL LIMITED is an Australian biopharmaceutical company focused on developing treatments for serious diseases. It is listed on the Australian Securities Exchange, XASX.